Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed CLL or SLL and satisfying at least 1 of the following criteria for requiring treatment:~   * Progressive splenomegaly and/or lymphadenopathy identified by physical examination or radiographic studies~  * Anemia (\<11 g/dL) or thrombocytopenia (\<100,000/μL) due to bone marrow involvement~  * Presence of unintentional weight loss \> 10% over the preceding 6 months~  * NCI CTCAE Grade 2 or 3 fatigue~  * Fevers \> 100.5° or night sweats for \> 2 weeks without evidence of infection~  * Progressive lymphocytosis with an increase of \> 50% over a 2 month period or an anticipated doubling time of \< 6 months~2. 1 to 3 prior treatment regimens for CLL/SLL~3. ECOG performance status of ≤ 1~4. ≥ 18 years of age~5. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty~6. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations)~Exclusion Criteria:~1. Any chemotherapy, therapeutic antineoplastic antibodies (not including radio- or toxin immunoconjugates), radiation therapy, or experimental antineoplastic therapy within 4 weeks of first dose of study drug~2. Radio- or toxin-conjugated antibody therapy within 10 weeks of first dose of study drug~3. Concomitant use of medicines known to cause QT prolongation or torsades de pointes~4. Transformed lymphoma or Richter's transformation Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk~5. Any of the following laboratory abnormalities: oAbsolute neutrophil count (ANC) \< 1000 cells/mm3 (1.0 x 109/L) oPlatelet count \< 50,000/mm3 (50 x 109/L) oSerum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ≥ 3.0 x upper limit of normal (ULN) oCreatinine \> 2.0 x ULN or creatinine clearance \< 40 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR) (Type: EXPERIMENTAL): None
- PCI-32765 plus bendamustine/rituximab (BR) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).